Medtronic Inc.

Solutions for people with chronic disease

Medtronic, Inc. (NYSE: MDT) provides lifelong solutions for people with chronic disease. Medtronic Sofamor Danek, the company’s Spinal business, is committed to advancing the treatment of spinal and cranial disorders. The company was founded April 29, 1949 in Minneapolis, Minnesota, USA, by Earl E. Bakken and Palmer J. Hermundslie. Medtronic has five divisions: Medtronic Cardiac Rhythm Management (CRM), Medtronic Cardiac Surgery, Medtronic Vascular, Medtronic Neurological and Diabetes, Medtronic Spinal, ENT and SNT.

William A. Hawkins, President & CEO
Michael Demane, COO
Gary Ellis, CFO

710 Medtronic Parkway
Minneapolis, MN 55432-5604
USA
Phone: +1-763-514-4000
Fax: +1-763-514-4879

INFUSE Bone Graft was approved by the FDA in May 2004 for the treatment of acute, open fractures of the tibial shaft. The approval broadens the indications for INFUSE Bone Graft (has been on the market since 2002). INFUSE Bone Graft contains recombinant human bone morphogenetic protein (rhBMP-2), the genetically engineered version of a naturally occurring protein that is capable of inducing bone growth at the site of implantation. Further information is provided at www.infusebonegraft.com.

The ENDEAVOR III trial is a 436-patient, randomised trial evaluating the safety and efficacy of Endeavor compared to the Cypherâ„¢ drug-eluting stent marketed by Cordis Corporation, a Johnson & Johnson company.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.